An experimental once-weekly injection copying amylin, the fullness hormone, acting on a different appetite pathway than established weight-loss injections. Weight loss grows with dose, with waist, blood fats, blood sugar, inflammation, blood pressure and physical capability improving. Nausea, fatigue, altered bowel habit and stopping treatment rise with dose. Evidence is manufacturer-funded and under a year; the drug is unapproved. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Body weight (percent change) | −10% or more from baseline by 48 weeks | Primary effect; defines response |
| Waist circumference | Below 94 cm (men), below 80 cm (women) | Tracks central fat, the metabolically active depot |
| Lean body mass (scan) | No decline beyond 25% of total weight lost | Distinguishes useful fat loss from muscle loss |
| Glycated hemoglobin | 4.8–5.3% | Detects drift in average blood sugar |
| Fasting insulin | 2–5 µIU/mL | Detects insulin resistance improving or persisting |
| Apolipoprotein B | Below 80 mg/dL, below 60 mg/dL if high risk | Counts atherogenic particles better than cholesterol alone |
| Lipid panel | Triglycerides below 80 mg/dL; HDL above 55 mg/dL | Tracks the lipid improvements seen in trial |
| High-sensitivity C-reactive protein | Below 0.5 mg/L | Tracks inflammation falling with fat loss |
| Estimated glomerular filtration rate | Above 90 mL/min/1.73 m² | Kidney handling of the drug is not yet characterized |
| Liver enzymes (ALT) | Below 25 U/L (men), below 20 U/L (women) | Hepatic impairment studies are still running |
| Vitamin B12 and ferritin | B12 above 500 pg/mL; ferritin 50–150 ng/mL | Reduced intake can deplete both silently |
| Blood pressure | Below 120/80 mmHg | Tracks the reduction reported in trial |
Cadence: Baseline panel before the first injection; tolerability and weight at weeks 4 and 8; full laboratory panel repeated at week 12 and week 24, then every six months while dosing continues; body composition reassessed at six and twelve months.